Guanylate cyclase C agonists: Emerging gastrointestinal therapies and actions

Gastroenterology

Volumn 148, Issue 3, 2015, Pages 483-487

  Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANALGESIC AGENT; BILE ACID; CHLORIDE; CYCLIC GMP; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOKINE; ESCHERICHIA COLI ENTEROTOXIN; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; GUANYLATE CYCLASE C; LAXATIVE; LINACLOTIDE; LUBIPROSTONE; MESSENGER RNA; PHOSPHODIESTERASE; PLECANATIDE; UNCLASSIFIED DRUG; UROGUANYLIN; ATRIAL NATRIURETIC FACTOR RECEPTOR; GASTROINTESTINAL AGENT; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR C; PEPTIDE;

ABDOMINAL PAIN; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; COLON ADENOCARCINOMA; COLON POLYPOSIS; CONSTIPATION; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DIARRHEA; DRUG EFFICACY; ESCHERICHIA COLI; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MUCOSA; GENE MUTATION; HUMAN; INTESTINE EPITHELIUM CELL; IRRITABLE COLON; LIGAND BINDING; MECONIUM ILEUS; META ANALYSIS (TOPIC); MOUSE; NONHUMAN; NOTE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; TRAVELLER DIARRHEA; TREATMENT RESPONSE; AGONISTS; COLON; COMPLICATION; DRUG EFFECTS; INTESTINE MUCOSA; IRRITABLE BOWEL SYNDROME;

APOPTOSIS; CHLORIDES; COLON; CONSTIPATION; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; NATRIURETIC PEPTIDES; PEPTIDES; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 84923879032     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.01.003     Document Type: Editorial

References (35)

1. T. Fiskerstrand, N. Arshad, and B.I. Haukanes Familial diarrhea syndrome caused by an activating GUCY2C mutation N Engl J Med 366 2012 1586 1595
2. H. Romi, I. Cohen, and D. Landau Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating guanylate cyclase 2C Am J Hum Genet 90 2012 893 899
3. M. Camilleri, P. Carlson, and A. Acosta RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study Am J Physiol 306 2014 G1089 G1098
4. L.R. Forte Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology Regul Pept 81 1999 25 39
5. Z. Li, B. Taylor-Blake, and A.R. Light Guanylin, an endogenous ligand for C-type guanylate cyclase, is produced by goblet cells in the rat intestine Gastroenterology 109 1995 1863 1875
6. A. Perkins, M.F. Goy, and Z. Li Uroguanylin is expressed by enterochromaffin cells in the rat gastrointestinal tract Gastroenterology 113 1997 1007 1014
7. N.S. Joo, R.M. London, and H.D. Kim Regulation of intestinal Cl- and HCO3-secretion by uroguanylin Am J Physiol 274 1998 G633 G644
8. L.R. Forte, and M.G. Currie Guanylin: A peptide regulator of epithelial transport FASEB J 9 1995 643 650
9. F.K. Hamra, S.L. Eber, and D.T. Chin Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity Proc Natl Adad Sci U S A 94 1997 2705 2710
10. K. Shailubhai, S. Comiskey, and J.A. Foss Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses Dig Dis Sci 58 2013 2580 2586
11. S. Rao, A.J. Lembo, and S.J. Shiff A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation Am J Gastroenterol 107 2012 1714 1724
12. W.D. Chey, A.J. Lembo, and B.J. Lavins Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety Am J Gastroenterol 107 2012 1702 1712
13. A.J. Lembo, H.A. Schneier, and S.J. Shiff Two randomized trials of linaclotide for chronic constipation N Engl J Med 365 2011 527 536
14. V. Andresen, M. Camilleri, and I. Busciglio Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome Gastroenterology 133 2007 761 768
15. E.J. Videlock, V. Cheng, and F. Cremonini Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis Clin Gastroenterol Hepatol 11 2013 1084 1092
16. DK1 Atluri, A.K. Chandar, and A.E. Bharucha Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis Neurogastroenterol Motil 26 2014 499 509
17. K. Matter, and M.S. Balda Signalling to and from tight junctions Nat Rev Mol Cell Biol 4 2003 225 236
18. A.S. Fanning, and J.M. Anderson Zonula occludens-1 and -2 are cytosolic scaffolds that regulate the assembly of cellular junctions Ann N Y Acad Sci 1165 2009 113 120
19. F. Wang, B.T. Schwarz, and W.V. Graham IFN-gamma induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction Gastroenterology 131 2006 1153 1163
20. X. Han, E. Mann, and S. Gilbert Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier PLoS One 6 2011 e16139
21. E.A. Mann, E. Harmel-Laws, and M.B. Cohen Guanylate cyclase C limits systemic dissemination of a murine enteric pathogen BMC Gastroenterol 13 2013 135
22. J. Castro, A.M. Harrington, and P.A. Hughes Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′,5′-monophosphate Gastroenterology 145 2013 1334 1346
23. I. Silos-Santiago, G. Hannig, and H. Eutamene Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation Pain 154 2013 1820 1830
24. H. Eutamene, S. Bradesi, and M. Larauche Guanylate cyclase C mediated antinociceptive effects of linaclotide in rodent models of visceral pain Neurogastroenterol Motil 22 2010 312-e84
25. W.E. Whitehead, O.S. Palsson, and L. Gangarosa Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome Neurogastroenterol Motil 23 2011 944-e400
26. D.A. Drossman, W.D. Chey, and J.F. Johanson Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies Aliment Pharmacol Ther 29 2009 329 341
27. K.A. Steinbrecher, E. Harmel-Laws, and M.P. Garin-Laflam Murine guanylate cyclase C regulates colonic injury and inflammation J Immunol 186 2011 7205 7214
28. E. Harmel-Laws, E.A. Mann, and M.B. Cohen Guanylate cyclase C deficiency causes severe inflammation in a murine model of spontaneous colitis PLoS One 8 2013 e79180
29. G.M. Pitari Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis Drug Des Devel Ther 7 2013 351 360
30. K. Shailubhai, H.H. Yu, and K. Karunanandaa Uroguanylin treatment suppresses polyp formation in the APCmin/+ mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP Cancer Res 60 2000 5151 5157
31. P. Li, S. Schulz, and A. Bombonati Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity Gastroenterology 133 2007 599 607
32. J.E. Lin, P. Li, and A.E. Snook The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling Gastroenterology 138 2010 241 254
33. N. Basu, R. Bhandari, and V.T. Natarajan Cross talk between receptor guanylyl cyclase C and c-src tyrosine kinase regulates colon cancer cell cytostasis Mol Cell Biol 29 2009 5277 5289
34. N. Basu, S. Saha, and I. Khan Intestinal cell proliferation and senescence is regulated by receptor guanylyl cyclase C and p21 J Biol Chem 289 2014 581 593
35. A. Deguchi, W.J. Thompson, and B. Weinstein Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells Cancer Res 64 2004 3966 3973